伊马替尼治疗隆突性皮肤纤维肉瘤：靶向治疗还是免疫治疗？

Imatinib in Dermatofibrosarcoma: Targeted Therapy or Immunotherapy?

机构信息

Department of Dermatology, University of Duisburg-Essen, Essen, Germany.

Department of Dermatology, University of Duisburg-Essen, Essen, Germany; Translational Skin Cancer Research, German Cancer Consortium, West German Cancer Center, Essen, Germany.

出版信息

J Invest Dermatol. 2017 Feb;137(2):277-279. doi: 10.1016/j.jid.2016.10.027.

DOI:10.1016/j.jid.2016.10.027

PMID:28110710

Abstract

There is increasing evidence that certain kinase inhibitors are able to foster two strategies, i.e. inhibition of oncogenic activated molecular pathways and modulation of immunological processes. In this respect, the study of Tazzari et al. is of great interest because it shows both effects for the kinase inhibitor imatinib in dermatofibrosarcoma protuberans.

摘要

越来越多的证据表明，某些激酶抑制剂能够促进两种策略，即抑制致癌激活的分子途径和调节免疫过程。在这方面，Tazzari 等人的研究非常有趣，因为它显示了激酶抑制剂伊马替尼在隆突性皮肤纤维肉瘤中的这两种作用。